CGP 22979A, a renal vasodilator with natriuretic properties
Renal vasodilation might be an interesting new antihypertensive principle. In the present study, the prodrug approach was adopted to synthesize a preferential renal vasodilator. A hydralazine-like compound, CGP 18137A (2-hydrazino-5-n-butyl-pyridine), was substituted with an N-acetyl-gamma-glutamyl...
Saved in:
Published in | The Journal of pharmacology and experimental therapeutics Vol. 232; no. 3; pp. 838 - 844 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Society for Pharmacology and Experimental Therapeutics
01.03.1985
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Renal vasodilation might be an interesting new antihypertensive principle. In the present study, the prodrug approach was
adopted to synthesize a preferential renal vasodilator. A hydralazine-like compound, CGP 18137A (2-hydrazino-5-n-butyl-pyridine),
was substituted with an N-acetyl-gamma-glutamyl residue. The resulting derivative, CGP 22979A [N-acetyl-L-glutamic acid-N[N2-(5-n-butyl-2-pyridyl)hydrazide]],
was inactive in the isolated perfused mesenteric artery, whereas the parent compound induced a dose-dependent inhibition of
vasoconstrictor stimuli. When administered i.v. to anesthetized rats in doses between 1.0 and 10.0 mg/kg, CGP 22979A increased
renal blood flow significantly, by up to 31% without affecting blood pressure. A dose of 4.0 mg/kg lowered renal vascular
resistance by 25% but did not alter total systemic, mesenteric and iliac vascular resistance. A dose of 10.0 mg/kg increased
glomerular filtration rate by up to 42%. In conscious rats, the same dose increased sodium excretion by 200%. Because CGP
22979A induces renal vasodilation in rats and has a preferential action on the afferent arterioles, it might be a useful tool
for studying the antihypertensive potential of renal vasodilation. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0022-3565 1521-0103 |